The Value of SUVmax of Gallium-68-PSMA PET/CT in Newly Diagnosed Prostate Cancer
Article Sidebar
Main Article Content
Abstract
OBJECTIVES: To evaluate the correlation between the intensity of prostate specific membrane antigen (PSMA) expression by Gallium-68-PSMA positron emission tomography/computer tomography (Ga-68-PSMA PET/ CT) and the D’Amico risk classification of newly diagnosed prostate cancer patients.
MATERIALS AND METHODS: Retrospective reviews of 61 newly diagnosed prostate cancer patients, who underwent Ga-68-PSMA PET/CT between September 2017 and November 2021. Data of maximum standard uptake value (SUV max) of prostate tissue was collected. The correlation between SUV maximum value and D’Amico risk classification, as well as Gleason score (GS) grade group and prostate specific antigen (PSA) level, was evaluated. For the data analysis, the Kruskal-Wallis test, Pearson correlation, and receiver operating characteristic curve (ROC curve) analysis were carried out.
RESULTS: Most of the patients (50 patients, 82%) were in the high risk D’Amico risk classification. The mean SUVmax values of the primary tumor for all patients were 15.7 ± 10.5. The SUVmax values for low and intermediate-risk patients (9.5 ± 4.76) were significantly lower than those of high-risk patients (17.06 ± 10.93) (p-value 0.013). A positive correlation was found between SUVmax values and the GS grade group (p-value 0.025), while there was a low correlation between PSA level and SUVmax values. The cutoff SUVmax value of 8.3 showed a sensitivity (84%) and specificity (63.6%) for the detection of high-risk prostate cancer.
CONCLUSION: PSMA expression in primary tumors is significantly higher in patients with higher GS grade groups and high-risk D’Amico staging, but it is not correlated with PSA level. Ga-68-PSMA PET/CT can be used to screen high-risk prostate cancer patients and potentially help in an individualized treatment decision.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-49. doi: 10.3322/caac.21660.
European Association of Urology. EAU Guidelines. Edn. on presented at the EAU Annual Congress Amsterdam 2022. ISBN 978-94-92671-16-5.
Demirci E, Kabasakal L, Şahin OE, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nuclear medicine communications. Nucl Med Commun 2019;40(1):86-91. doi: 10.1097/MNM.0000000000000942
Efesoy O, Bozlu M, Çayan S, et al. Complications of transrectal ultrasound-guided 12-core prostate biopsy: a single center experience with 2049 patients. Turk J Urol 2013;39(1):6-11. doi: 10.5152/tud.2013.002.
Wenzel M, Theissen L, Preisser F, et al. Complication rates after TRUS guided transrectal systematic and MRI-targeted prostate biopsies in a high-risk region for antibiotic resistances. Front Surg 2020;7:7. doi: 10.3389/fsurg.2020.00007.
Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395(10231):1208-16. doi: 10.1016/S0140-6736(20)30314-7.
Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008;63(4):387-95. doi: 10.1016/j.crad.2007.05.022.
Donswijk ML, van Leeuwen PJ, Vegt E, et al. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study. BMC Cancer 2020;20(1):723. doi: 10.1186/s12885-020-07192-7.
van der Sar EC, van Kalmthout LM, Lam M. PSMA PET/CT in primary prostate cancer diagnostics: an overview of the literature. Tijdsch Urol 2020;10(6):101-8. doi:10.1007/s13629-020-00297-5
Israeli RS, Powell CT, Corr JG, et al. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54(7):1807-11.
Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3(1):81-5.
Wang Z, Zheng A, Gao J, et al. The value of 18F-PSMA PET/CT in the diagnosis and prognosis of primary prostate cancer. Soc Nuclear Med 2021
Rahbar K, Weckesser M, Huss S, et al. Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer. J Nucl Med 2016;57(4):563-7. doi: 10.2967/jnumed.115.169243.
Woythal N, Arsenic R, Kempkensteffen C, et al. Immunohistochemical validation of PSMA expression measured by Ga-68-PSMA PET/CT in primary prostate cancer. J Nucl Med 2018;59(2):238-43. doi: 10.2967/jnumed.117.195172.
Wright Jr GL, Haley C, Beckett ML, et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urologic Oncology: Seminars and Original Investigations 1995;1(1):18-28. doi: 10.1016/1078-1439(95)00002-Y.
Han S, Woo S, Kim YJ, et al. Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 2018;74(2):179-90. doi: 10.1016/j.eururo.2018.03.030.
Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2016;40(2):244-52. doi: 10.1097/PAS.0000000000000530.
Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017;44(6):941-9. doi: 10.1007/s00259-017-3631-6.
Fajardo-Ordóñez ES, Pachuca-González D, Hernández-Ramírez R, et al. Correlation between levels of prostate specific antigen and SUVmax values in patients with prostate cancer evaluated with Ga-68-PSMA PET/CT. Anales de Radiología México 2020;19:1-10
Koerber SA, Utzinger MT, Kratochwil C, et al. 68Ga-PSMA-11 PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med 2017;58(12):1943-8. doi: 10.2967/jnumed.117.190314.
Oesterling JE, Rice DC, Glenski WJ, et al. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 1993;42(3):276-82. doi: 10.1016/0090-4295(93)90616-i.